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Abstract
Tenosynovial giant cell tumor (TSGCT) is a disease of
disputed etiology and pathogenesis. Some investiga-
tions indicate a neoplastic origin of the tumors; others
indicate that they are polyclonal and inflammatory. The
cytogenetic and molecular genetic features of TSGCTs
are largely unknown, as only some 20 localized and
30 diffuse tumors with cytogenetic aberrations have
been reported. The most common karyotypic aberra-
tions have been trisomy for chromosomes 5 and 7 and
translocations involving chromosomal area 1p11–13.
We decided to screen the genomes of TSGCTs by
comparative genomic hybridization (CGH) to perform
interphase fluorescence in situ hybridization (IP-FISH),
looking for numerical aberrations of chromosomes 1,
5, and 7, and to analyze the tumors for microsatellite
instability. Except for two diffuse TSGCTs that came
fresh to us, and which, by karyotyping, exhibited
t(1;22)(p13;q12) and a t(1;1)(q21;p11) and +7, respec-
tively, all studies had to be performed on formalin-
fixed, paraffin-embedded material. DNA was extracted
from 51 localized and nine diffuse TSGCTs. CGH was
successful for 24 tumors, but none of them showed
copy number changes. The IP-FISH studies showed
trisomy 7 in 56% of the tumors (15/27), whereas chro-
mosomes 1 and 5 seemed to be disomic in all TSGCTs.
All informative tumors were wild-type by microsatellite
instability analysis.
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Introduction
Tenosynovial giant cell tumor (TSGCT), also called nodular
tenosynovitis or (pigmented) villonodular synovitis, tenosyn-
ovitis, and bursitis [1], presumably arises from the synovium
of tendon sheaths, joints, or bursae [2]; mostly affects adults
between 30 and 50 years of age; and is slightly more
common in women. Microscopically, the lesion consists of
mononuclear, xanthomatous, and giant cells with variable
degrees of collagenization, and it may or may not be well
circumscribed by a dense, collagenous capsule. TSGCTs
may be either intraarticular or extraarticular, diffuse or
localized [3–5]. A mass, joint swelling, and/or pain is the most
common presenting sign and symptom.
As is apparent from the variable-naming practices alluded to
above, considerable uncertainties exist as to the pathogenetic
mechanisms behind TSGCTs. Lyonization studies have shown
a random pattern of X-inactivation [6,7] and TSGCT-like
lesions have been produced experimentally with inflammatory
agents [8], both suggesting a polyclonal and inflammatory
pathogenesis. In contrast, another X-inactivation study found
that the lesion was monoclonal [9], and also the detection of
clonal chromosomal aberrations [4] and DNA aneuploidy [10]
in TSGCTs point toward a neoplastic disease process. The
reports of metastasizing TSGCTs [11–15] and their sometimes
invasive growth further support the neoplastic hypothesis.
The cytogenetics and molecular genetics of TSGCT are
not well known. To our knowledge, only 33 diffuse tumors
[1,16–24] and 23 localized TSGCTs [1,22] have been karyo-
typed. The most frequent findings are trisomy 7 and/or trisomy
5 as well as translocations, both balanced and unbalanced, in-
volving chromosomal areas1p11–13, 2q35–37, and16q22–24.
Interphase fluorescence in situ hybridization (IP-FISH) with
probes specific for chromosome 7 has also been performed,
revealing variable percentages of trisomy 7 [16,18,21].
In an attempt to further extend our knowledge about the
genomic changes of these tumors, we decided to perform
comparative genomic hybridization (CGH) and IP-FISH with
probes specific for chromosomes 1, 5, and 7. The former type
of analysis has never been performed on TSGCTs before. In
addition, we present the karyotypes of three diffuse TSGCTs
subjected to chromosome banding analysis. Because in colon
cancer there is an association between a diploid tumor karyo-
type and an abundance of inflammatory cells, on one hand, and
microsatellite instability, on the other hand [25], and because
the former two features are also seen in TSGCT, we also chose
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to perform analysis of the microsatellite markers BAT25 and
BAT26 to look for microsatellite instability [26,27].
Materials and Methods
Samples and Cytogenetics
Fifty-eight consecutive formalin-fixed, paraffin-embedded
(FFPE) TSGCTs arriving at our hospital between 1998 and
2002 and two fresh frozen TSGCTs were obtained from the
Department of Pathology. Fifty-one of the FFPE tumors were
localized, whereas the remaining seven were of the diffuse
type, as were also the two fresh frozen tumors. Thirty-seven
of 60 (62%) tumor samples were from women, and 23 (38%)
were from men. Seven tumors were recurrences and 53
were primary tumors. The median patient age at diagnosis
was 44 years (range 14–77 years). For the subset of diffuse
tumors, median patient age was 30 years, three of nine
samples were recurrences, and five patients were male.
Table 1 summarizes the clinical and molecular cytogenetic
data on the 27 tumors analyzed by IP-FISH (see below).
The two tumors that were surgically removed at The
Norwegian Radium Hospital while the studies on archival
material were in progress were processed for cytogenetic
analysis. Fresh material was manually minced and treated
with collagenase, hyaluronidase, and neuraminidase until a
suitable suspension of cells and cell clumps was obtained.
After 3 days of culturing in a medium consisting of RPMI
1640, 13% fetal calf serum, and antibiotics, colchicine was
added for the last 4 hours and the short-term culture was
harvested according to standard protocols [28]. The chro-
mosomes in the dividing cells were then G-banded and a
karyotype was established in accordance with the recom-
mendations of the International System of Cytogenetic No-
menclature [29]. This procedure had also been carried out
earlier on one of the FFPE tumors.
CGH
DNA was isolated by the phenol chloroform method as
previously described [30]. Briefly, the tissue was deparaffi-
nized in xylene, washed in alcohol, and digested in lysis
buffer, proteinase K, and RNAse, followed by phenol chlo-
roform extraction and ethanol precipitation. Metaphase tar-
get slides were prepared by dropping fixed cells from
peripheral blood of a healthy person onto moist slides. The
preparations were evaluated according to the following cri-
teria: adequate chromosomal length, black color, minimal
overlapping, minimal cytoplasm, and adequate number of
mitoses [31]. Slides were stored at room temperature 1 to
4 weeks before use.
CGH was performed on 49 of 60 tumors as previously
described [32–34], with minor modifications. For the remain-
ing 11 tumors, no high-molecular-weight DNA (HMW-DNA)
was obtained. Briefly, equal amounts of test and reference
DNA were differentially labeled with fluorochrome-conjugat-
ed nucleotides, mixed together, denatured at 70jC for 5
minutes together with 33 mg of human cot-DNA, and then
hybridized onto normal metaphase spreads that had been
denatured for 3 minutes at 70jC to 73jC. The samples were
then incubated at 37jC for 2 to 3 days. After washing, the
slides were counterstained with an antifade solution consist-
ing of 4V,6-diamino-2-phenylindole (DAPI) and Vectashields
H-1200 (Vectashield; Vector Laboratories, Burlingame, CA),
and examined in a fluorescence microscope (Zeiss Axioplan,
Oberkochen, Germany). Single-color images [fluorescein
isothiocyanate (FITC), Texas Red, and DAPI] of metaphase
spreads were sequentially photographed with a Cohu 4900
CCD (12-bit gray scale) camera, using Cytovision hardware
and software.
Chromosomes were karyotyped based on their inverted
DAPI banding appearance. Fluorescence ratio profiles
(green to red) were calculated for individual chromosomes,
data from 11 to 20 representative copies of each chromo-
some were combined, and average ratio profiles with 95%
confidence intervals were calculated for each tumor. The
centromeric and pericentromeric heterochromatic regions
were not evaluated. Poor hybridizations, mostly resulting
from either suboptimal slide or DNA quality, were not ac-
cepted. One knows from karyotyping studies that TSGCTs
are mostly diploid, and we therefore chose thresholds
corresponding to loss or gain of one chromosome homo-
logue in 50% of the cells analyzed (i.e., 0.75 and 1.25,
respectively). To reduce the problem with potentially false-
positive areas [32,33,35], we used a modified CGH protocol
with a mixture of fluorochrome dUTP and dCTP during nick
translation. Additionally, we also used a negative control in
Table 1. Clinical and Molecular Cytogenetic Data on 27 TSGCTs.
Sample
Number
Subtype Location Recurrence Sex Age CGH Trisomy
7 (%)
03-02 L Finger F 26 Normal 1
05-02 L Hand + F 71 Normal 3
06-02 L Finger F 27 Normal 3.5
11-02 L Knee F 38 Normal 11
12-02 L Finger M 77 Normal 6.5
14-02 L Finger M 31 Normal 9
18-02 L Finger F 59 Normal 8
25-02 L Finger F 27 Normal 3
26-02 L Hand F 41 Normal 5
27-02 L Finger M 35 Normal 6.5
28-02 L Hand F 53 Normal 5.5
30-02 L Finger F 36 Normal 0
31-02 D Knee M 15 Normal 5.5
32-02 L Finger M 64 Normal 6
33-02 L Ankle M 18 Normal 6.5
35-02 L Finger F 35 Normal 1
41-02 L Foot + M 50 Normal 0
43-02 L Finger F 58 Normal 9.5
48-02 D Hand + F 36 Normal 8.5
53-02 L Finger F 41 Normal 2
54-02 D Finger + F 55 Normal 7
57-02 L Finger M 43 Normal 0
59-02 D Knee F 14 Normal 7
R02-885 D Unknown F 20 Normal 0
13-02 D Knee M 33 ND 1.5
46-02 D Hand + M 20 ND 3
52-02 D Knee M 28 ND 10.5
L, localized; D, diffuse; +, recurrence; M, male; F, female; ND, not
determined.
Trisomy 7 percentages in italics when more than 5% of the cells in a sample
showed three signals for the chromosome 7–specific probe.
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all experiments, and all tumor changes were evaluated
against this control. Finally, the human colon cancer cell line
lovo was used as a positive control in each experiment.
IP-FISH
Dual-color IP-FISH with a-satellite probes specific for
chromosomes 1 and 7, and with a dual-color probe for
chromosome arms 5p and 5q, was performed on 27
TSGCTs altogether. Directly labelled spectrum green and
spectrum orange probes and appropriate hybridization and
counterstaining solutions were supplied by Vysis (AH Diag-
nostics, Oslo, Norway). The tumors with informative CGH
results and three of the other four diffuse TSGCTs were
included; for the fourth one, no more material was available.
The nuclei were extracted by a method modified from Liehr
et al. [36]. Briefly, two to four 50-mm tissue sections were
deparaffinized in xylene and washed in alcohol before
rehydration. The preparations were then washed in phos-
phate-buffered saline (PBS), prewarmed protease (Sigma
Protease XXIV; 0.5 mg/ml) in PBS was added, and the
preparations were incubated in a shaking water bath for
1 hour at 37jC. The resulting cell suspensions were then
pipetted vigorously to release nuclei, filtrated through a
60-mm nylon mesh, followed by centrifugation and washing
in PBS. Finally, the nuclear suspension was spread on poly-
L-lysine–coated slides using a cytospin centrifuge. The
slides were left at room temperature for one night before
freezing at 70jC or 20jC.
From the day before hybridization was begun, the slides
were kept at room temperature and pretreated as described
earlier with but minor modifications [37]. Briefly, the slides
were treated with xylene in order to remove remaining
paraffin, and washed in alcohol. The preparations were then
boiled for 15 minutes in a microwave oven and cooled for 20
minutes at room temperature; both procedures took place
with the slides immersed in sodium citrate. Finally, the slides
were treated with variable concentrations of pepsin (P-7012;
Sigma-Aldrich, Steinheim, Germany) for 5 to 13 minutes,
washed in PBS, and dehydrated in alcohol.
For denaturation and hybridization of probes and slides,
we used the following procedure [38]. The dehydrated slides
were denatured in formamide at 73jC for 5 minutes, dehy-
drated again, and dried. The probes were denatured at 73jC
for 5 minutes before application onto the slide. After 2 to 3
days of incubation at 37jC to 42jC, the slides were washed
in formamide, 2  standard saline citrate (2  SSC), and
2  SSC/0.1% NP-40. Then air drying was carried out
before application of 10 ml of DAPI in antifade solution and
sealing with a coverslip. Two hundred successive, whole,
and single nuclei were examined in a Zeiss fluorescence
microscope and images were captured using a Cohu cam-
era. The specificity of the probe was validated by FISH
experiments on slides with metaphases and interphase
nuclei from a karyotypically normal person.
Cutoff levels for defining trisomy in IP-FISH studies vary
in the literature, mostly from 5% to 10%.We chose to use 5%
as the cutoff level based on findings on control slides and the
results reached using chromosome 1–specific, chromo-
some arm 5p–specific, and chromosome arm 5q–specific
probes; for none of them, more than 3.0% of the cells
showed three signals. The probes for chromosomes 1 and
7 were cohybridized, and, in this way, the first of them served
as an internal control.
Microsatellite Instability Analyses
Duplex polymerase chain reaction (PCR) analyses of two
mononucleotide microsatellites (BAT25 and BAT26) were
performed using a fluorescent-labeled forward primer and
PCR conditions as described earlier [39]. The PCR products
were separated by capillary electrophoresis on an ABI
PRISM310GeneticAnalyzer (PEBiosystems,Oslo,Norway).
Because these microsatellites are quasimonomorphic, only
tumor DNA was analyzed. Samples with a PCR product
within the correct size range were considered informative.
Results
Samples and Cytogenetics
One of the three tumors subjected to G-banding analysis
had a normal karyotype. The second tumor had a t(1;22)
(p13;q12) in all 20 cells analyzed (Figure 1A), whereas the
third tumor had a t(1;1)(q21;p11) in nine cells (Figure 1B), an
unrelated clone with +7 as the only aberration in two cells,
and 14 cells were normal. All three were of the diffuse type.
CGH
Eleven of 58 FFPE tumor samples did not yield any HMW-
DNA at all, but 22 of the remaining 47 FFPE TSGCTs could
be analyzed by CGH, as were the two fresh frozen TSGCTs.
Nineteen of the successfully analyzed tumors were localized.
All genomic profiles were normal. For 25 of the TSGCTs, the
hybridizations were not satisfactory, and these tumors were
therefore not analyzed by CGH.
IP-FISH
Trisomy 7 was detected in 15 of 27 samples (56%) as
analyzed by IP-FISH (Figure 2, Table 1). There was no
striking difference between localized and diffuse tumors, as
five of eight (63%) diffuse tumors and 10 of 19 (53%)
localized tumors exhibited trisomy 7. Three signals for chro-
mosome 1 and chromosome arms 5p and 5q were detected
in 0% to 2.5%, 0% to 3%, and 0% to 3% of the cells in each
sample, respectively. As this is below our cutoff limit, no
trisomies for these probes were detected.
Microsatellite Instability Analyses
Fifty-two of the tumors were wild-type for BAT25; for the
remaining eight tumors, the analyses were not successful.
The corresponding numbers for BAT26 were 53 wild-type
tumors and seven tumors with unsuccessful analysis.
Discussion
Based on earlier studies by others and from our own previ-
ous work with CGH on FFPE material, we know that the
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success rate is fairly low but variable [30,40,41]. The reasons
for this are, first and foremost, the problems associated with
degraded DNA and parameters relevant to the fixation
process, the time the samples spent in fixative, and the
composition of the fixation fluid. All tumors in the present
series were routinely treated in buffered formalin. For the 11
TSGCTs that yielded no HMW-DNA, it was of course impos-
sible to proceed with CGH. For the 25 tumors with some
HMW-DNA but which nevertheless gave no satisfactory
hybridization by CGH, we can only speculate that they had
spent a relatively long time in formalin because we have no
specific information for individual samples regarding this
matter.
The pathogenetic mechanism(s) of TSGCTs has been
debated much, as has the nosologic position and subgroup-
ing of this imprecisely defined entity. The confusing termi-
nology reflects this state of affairs: some names imply an
inflammatory pathogenesis (itis), others a neoplastic one
(tumor). Additionally, the distinction between diffuse and
localized and/or between extraarticular and intraarticular
lesions is not always precise. Some authors tend to see the
lesions as histopathologically similar but clinically distinct
[10], whereas others regard themasonediseaseentity [3,42].
We included 60 consecutive TSGCTs in our study, 51 of
them of the localized type. Most patients were in the age
group 25 to 60 years, and most of them were women, which
is in accordance with known incidence data [2]. In previous
studies [1,16–24], 26 of 33 hitherto karyotyped diffuse
TSGCTs have been demonstrated to carry clonal chromo-
somal aberrations, whereas the corresponding number for
localized tumors is 15 of 23 [1,22]. We now add karyotypic
data on three diffuse TSGCTs: one normal, one demonstrat-
ing a t(1;22)(p13;q12) as the sole chromosomal change, and
one exhibiting a t(1;1)(q21;p11) in nine cells and an unrelat-
ed clone with +7 as the only aberration in another two cells.
1p11–13 is the chromosomal region most frequently in-
volved in structural rearrangements in TSGCTs, together
with different translocation partners [1,22]. 22q12 and 1q21
have not been reported rearranged together with 1p11–13
in TSGCTs before. How the observed translocations might
act pathogenetically is unknown.
Because acquired genomic abnormalities are a hallmark
of neoplastic cells and because the nature of TSGCT is still
debated, we decided it was of interest to screen the genome
of these disease lesions by chromosomal CGH to look for
loss or gain of genetic material. It is important to remember
that this method is unable to detect balanced rearrange-
ments, some of which have been found by karyotyping in
TSGCTs. Another limitation of the technique is that it only
detects changes present in many cells in a sample, and one
should keep in mind that TSGCTs contain a considerable
admixture of many different cell types. If a neoplastic paren-
chyma exists in TSGCTs, it is therefore severely diluted by
other elements. Finally, small deletions and gains (<10 Mb)
Figure 1. (A) Partial karyotype from the diffuse TSGCT of case 46-02
showing normal chromosomes 1 and 22 paired up with the derivative
chromosomes 1 and 22 resulting from the t(1;22)(p13;q12) that was the only
chromosomal aberration of this case. (B) Partial karyotype from the diffuse
TSGCT of case 59-02 showing the two copies of chromosome 1 resulting
from a t(1;1)(q21;p11), the only structural chromosomal aberration of this
case.
Figure 2. IP-FISH image from case 14-02 showing three signals for the FITC-
labeled (green) chromosome 7–specific probe and two signals for the Texas
Red– labeled (red) chromosome 1–specific probe.
Molecular Cytogenetics of TSGCT Brandal et al. 581
Neoplasia . Vol. 6, No. 5, 2004
are not detectable by chromosomal CGH. All these aspects
are important for the interpretation of the results. Obviously,
the fact that all analyzable samples were normal by CGH
does not argue for a neoplastic origin of TSGCTs, but it
does not strongly contradict it either, given the aforemen-
tioned limitations.
Nor did the microsatellite analyses shed much light on the
pathogenetic process of TSGCT because all informative
tumors were wild-type for both BAT25 and BAT26. Never-
theless, this negative finding makes the possibility of micro-
satellite instability as a major contributing pathogenetic
mechanism in TSGCT unlikely.
There are some issues regarding our IP-FISH analyses
that need to be addressed. First, there are different cell types
in TSGCTs, and when we extract nuclei, all types of cells/
nuclei are treated the same. Because at least some of these
cells supposedly are nonneoplastic, the findings by IP-FISH
are correspondingly diluted, as it is impossible to know which
type of cell any individual nucleus represents. Second, we
were not able to perform investigations of chromosomes 5
and 7 on the same cells. However, this fact cannot affect the
actual frequencies of trisomies detected.
The IP-FISH results for chromosome 7 were of consider-
able interest. In previous studies, only diffuse TSGCTs have
been examined with chromosome 7–specific probes to
check for trisomy 7, the most frequent numerical aberration
found by karyotyping in these tumors, as it has been found in
8 of 26 (31%) aberrant cases [43]. Trisomy 7 percentages
between 3.0% and 26.5% were seen [16], and +7 could also
be found by IP-FISH in cases which by karyotyping had been
normal [21]. We examined both diffuse and localized
TSGCTs, finding similar frequencies of trisomy 7 in both. In
total, 56% of TSGCTs (15 of 27) exhibited trisomy 7 at
frequencies from 5.0% to 11% of all cells. Our results thus
confirm that trisomy 7 is a common aberration in TSGCT and
also show that there is no difference between diffuse and
localized disease in this regard.
Trisomy 7 is a controversial aberration in cancer cytoge-
netics as it can sometimes be found also in nonneoplastic
disease lesions and in normal tissues [44], underscoring that
the acquisition of somatic mutations is not always sufficient
to unleash neoplastic behavior by the cells harboring them. It
has been speculated that inflammatory cells may be more
prone to acquire +7 than other cell types and that this could
be the reason behind the finding of trisomy 7 also in chronic
inflammatory lesions [44]. Also many other studies and
reviews [17,21,45] have concluded that trisomy 7 may be
found in a number of inflammatory conditions including
different types of synovitis, both in vitro and in vivo, and cells
with +7 are suggested to have a polyclonal origin and a
proliferative advantage in vitro in some of these cases [17]. It
has been proposed that trisomy 7 might be a result of local
inflammatory mechanisms [46] and that the aberration
reflects an intermediate state between self-limiting inflam-
mation and neoplastic transformation. Furthermore, the fre-
quency of +7 has been reported to increase with age in both
nonneoplastic synovia and solid tumors, often as the sole
change in nonneoplastic tissue [47]. This was not markedly
so in the present study, in which the mean patient age for
trisomy 7–positive samples was about the same as the
mean age for the total sample material (42 vs 44 years),
whereas the mean age for the +7–negative samples was
only 36 years. At the same time, trisomy 7 has also been
reported as an early imbalance in many neoplasms, presum-
ably signifying an important early event in the development of
some tumors [48]. In conclusion, therefore, our finding of
trisomy 7 by IP-FISH in TSGCTs can be interpreted as
conclusive support for neither the neoplastic nor the inflam-
matory theory of pathogenesis. This is particularly so when
we consider that trisomy 7 was the only registered chro-
mosomal abnormality in this series, making its information
value in this regard even more uncertain.
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